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INTRODUCTION:  To illustrate  the  potential  side  effects  and  clinical  efﬁcacy  of  Botox  injections  in treating
sialorrhoea.
PRESENTATION  OF CASE:  A 26-year-old  patient  with  cerebral  palsy  with  dystonia  had  a long  history  of
severe,  distressing  sialorrhoea.  She was  treated  with  three  separate  Botox  injections  into  her  salivary
glands  in December  2011,  July  2012  and  March  2013.
DISCUSSION:  Following  the  Botox  injections  the  patient  developed  dysphagia,  began to  expectorate  thick
mucus  and  developed  a cough;  she  was  treated  for  a chest  injection  and  during  this  time  her  feeding
deteriorated.  Three  injections  were  given  as  the  patient  had  an  objective  and  signiﬁcant  reduction  in
salivation.  However,  the  side  effect  proﬁle  was deemed  too  great  to  continue  with  treatment.
CONCLUSION:  Botox  is a novel  and effective  treatment  for reducing  saliva  production.  Its clinical  efﬁcacy  is
supported  by this  case  and  correlates  with  the  recent  literature.  Although  rare,  signiﬁcant  side  effects  can
happen and  the  case  presented  illustrates  the  care  needed  when  administering  injections,  particularly  in
a subgroup  of  patients.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
access  article  under  the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Pathological sialorrhoea can be due to intrinsic hypersalivation
r occur secondary to neurological disorders such as amyotrophic
ateral sclerosis (ALS), cerebral palsy (CP), Parkinson disease (PD), or
s a side effect of medications.1 It can cause both psychological and
hysiological distress to patients. In children, the most common
ause of sialorrhoea is CP with hypersalivation occurring in 10–38%
f patients.2 In adults, PD is the most common cause with 70–80% of
D patients demonstrating sialorrhoea.3 Sialorrhoea resulting from
eurological conditions has a complex aetiology and is produced by
mpaired swallowing as a result of compromised neuromuscular
unction and aberrant coordination of the oral, facial and lingual
usculature.1
Botulinum toxin (BoNT) is a neurotoxin that blocks the release of
cetylcholine and a number of other neurotransmitters from synap-
ic vesicles.4 Its effect on drooling was ﬁrst noticed in patients with
arkinson disease and has been reported to be effective in the treat-
ent of sialorrhoea in numerous case studies, clinical trials and
etrospective studies.4 At present, three type A and one type B tox-
ns are in clinical use; onabotulinumtoxinA, abobotulinumtoxinA,
ncobotulinumtoxinA, and rimabotulinumtoxinB.1
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A 26-year-old patient with cerebral palsy had suffered from
sialorrhoea all her life. She was treated with three separate Botox
injections into her salivary glands in December 2011, July 2012 and
March 2013. After the ﬁrst Botox injection she developed breathing
difﬁculties, a nocturnal cough, produced thick mucus and seemed
to choke whilst eating, suffering from dysphagia. Two courses of
antibiotics were given, but they had no clinical effect. The patient
gradually improved, but her appetite was still reduced.
After the second injection the patient’s feeding deteriorated
again and she developed dysphagia and a distaste of her food. Also,
she started to produce more thick mucus and choked at night. She
was assessed by a speech and language therapist who advised a soft
mash/pureed diet with thickened drinks. In addition to this she was
prescribed carbocysteine that did have some effect. Over the next
few months her feeding proved very difﬁcult with frequent chok-
ing episodes and a general distaste for food leading to a reduced
appetite and weight loss.
Despite the side effects listed above the Botox injection were
effective at treating the patient’s sialorrhoea and she found this
socially more acceptable and comfortable. Therefore a further
Botox injection was  administered. Within three days her feeding
deteriorated alarmingly as noted by her parents. She began choking
on all food and drinks, with severe episodes making her nauseous
and pale. Moreover, taking her oral medication was  difﬁcult and
she was  expectorating thick viscous mucus.
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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The parents of the patient declared that there was  no doubt in
heir minds that the side effects described above were associated
ith the administration of Botox into her salivary glands.
. Discussion
BoNT is an established treatment option to treat hypersalivation.
uster Torres et al.5 stated that a signiﬁcant reduction was  observed
n the production of saliva following injections in a number of stud-
es and the duration of the therapeutic effect was 1.5–6 months.5
ay and Penn6 also noted a statistically signiﬁcant decrease in
rooling in a peadiatric population.5 The case presented here val-
dates the clinical efﬁcacy of Botox in treating sialorrhoea and the
atient’s carers acknowledged an objective reduction in drooling.
Botox injections are a less invasive treatment strategy for sial-
rrhoea compared to surgery. Various surgical procedures are
vailable, such as salivary gland duct ligation that is usually used
s a last resort when other methods have failed and in severe
efractory cases. Behaviour modiﬁcation techniques, correction of
ituational factors and oral-motor therapy are other treatment
ptions, but do not always produce a consistent improvement. Oral
gents, such as glycopyrrolate, and topical agents are also offered
ith varying degrees of success. A potential disadvantage of Botox
njections is the array of side effects that can be encountered as
llustrated in this case. However, in a large scale study Amrita Lakraj
t al.1 deﬁned side effects as uncommon and manageable when
njections were delivered at experienced centres.
Chan et al.7 recently performed a review of the long-term safety
nd efﬁcacy of Botox injections for sialorrhoea in 69 children. They
eclared that postinjection complications occurred in 19 patients
23 events). This was fourteen patients (15 events) with minor
nd ﬁve (8 events) with major complications. Major complications
ncluded aspiration pneumonia (n = 3), severe dysphagia (n = 2), and
oss of motor control of the head (n = 3), resulting in 5 hospitaliza-
ions and 2 nasogastric tube insertions. The patient in our report
id suffer from dysphagia, and possibly a chest infection, but did
ot require hospitalization.
In contrast, Amrita Lakraj et al.1 concluded that along with a
igniﬁcant positive clinical effect in patients BoNT had a limited
ide effect proﬁle. They stated hypersalivation in 3.9%, dysphagia
n 3.3%, xerostomia in 3.3% and pneumonia in 2.2% of patients. The
ide effects listed here are only apparent in a small minority of the
atient sample, but the adverse effect seem characteristic.
As Botox injections are frequently used in patients with pre-
xisting dysphagia and other oropharyngeal neurological deﬁcits
he side effect of dysphagia may  be signiﬁcant. Any exacerbation
f swallowing difﬁculties could have the potential to cause aspira-
ion pneumonia.8 Dysphagia may  result from inaccurate injection
f the Botox into the salivary glands signifying the importance of
ocalizing the correct site before the drug is administered.
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4. Conclusions
Numerous studies validate the clinical efﬁcacy of Botox injec-
tions in sialorrhoea and the patient presented here supports this
data. There is also a wealth of information describing potential
side effects of Botox injections, but these are only experienced in
a minority of patients. This case is an unusual example of signiﬁ-
cant side effects resulting from Botox treatment. Also, the cardinal
side effects experienced by the patient correlate with reported side
effects in the literature, notably dysphagia, increased mucus expec-
toration and possibly a chest infection. This illustrates the need to
consider possible side effects when giving Botox injections as they
have the potential to cause signiﬁcant morbidity, particularly in
patients with severe neurological disorders.
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